Biomarker-Based Lung Cancer Screening Eligibility: Implementation Considerations

With the convergence of promising biomarkers for lung cancer risk stratifications, and the increasing need for better eligibility assessment for lung cancer low-dose CT (LDCT) screening, the elephant in the room now is whether and how the implementation of biomarker-based lung cancer screening eligibility can be successfully achieved. This brief commentary provides an outline of key considerations for biomarker implementations for LDCT eligibility assessment and possible mitigation strategies.

Automated summary

This commentary outlines key considerations for biomarker implementations in LDCT eligibility assessment and possible mitigation strategies.